01 1Zhejiang Huahai Pharmaceutical
01 1EMPAGLIFLOZIN (PROCESS II)
01 1China
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2023-03-02
Pay. Date : 2023-01-18
DMF Number : 37867
Submission : 2022-12-23
Status : Active
Type : II
20
Zhejiang Huahai Pharmaceutical Co Ltd, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is EMPAGLIFLOZIN (PROCESS II), with a corresponding US DMF Number 37867.
Remarkably, this DMF maintains an Active status since its submission on December 23, 2022, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 02, 2023, and payment made on January 18, 2023, indicating their dedication to facilitating drug approvals, Categorized as Type II
